Welldoc, a leader in AI-driven cardiometabolic care, and Databricks, a leading Data and AI company, announced the expansion of their strategic partnership on July 22, 2025, building on their collaboration established in 2023. Welldoc’s formal inclusion in the Built on Databricks program leverages Databricks’ Data Intelligence Platform to enhance Welldoc’s analytics and proprietary AI, delivering hyper-personalized digital coaching for cardiometabolic conditions within the regulated healthcare environment.
Welldoc joins Databricks’ Built on Partner Program for enhanced AI capabilities
Integrates with Databricks’ Data Intelligence Platform for advanced analytics
Delivers personalized digital coaching for diabetes, hypertension, and more
Supports real-time biometrics from 400+ connected devices
FDA-cleared BlueStar® solution powers diabetes management
Partnership drives operational efficiency and go-to-market opportunities
Welldoc’s platform, including its FDA-cleared BlueStar® for type 1 and type 2 diabetes, provides AI-powered digital coaching for prediabetes, diabetes, hypertension, heart failure, weight management, and mental wellbeing. By integrating with Databricks’ platform, Welldoc unifies data from over 400 devices, including continuous glucose monitors and blood pressure cuffs, to deliver real-time, personalized insights. “Our expanded partnership with Databricks represents a significant advancement in our mission to deliver personalized, impactful cardiometabolic care within the rigorous standards of a regulated industry,” said Dr. Anand Iyer, Chief AI Officer at Welldoc.
The collaboration enhances Welldoc’s capabilities in three critical areas:
Next-Generation AI-Driven Coaching: Centralized data and evidence-based guidance enable tailored, in-the-moment support aligned with individual health needs.
Advanced Multivariate Analytics: Real-time sensor technology allows dynamic adaptation to user biometrics, improving intervention accuracy.
Refined Analytical Models: Predictive insights support individualized care journeys, empowering proactive and preventive care.
These advancements enable care teams to make timely clinical interventions, while health plans and systems gain population-level insights through Databricks’ Power BI reporting, optimizing chronic care programs.
With 90% of U.S. healthcare expenditures tied to chronic and mental health conditions, Welldoc’s platform addresses the economic burden of cardiometabolic diseases, which affect over 100 million Americans. The partnership tackles disparate data sources and interoperability challenges, streamlining data aggregation for actionable insights. “Welldoc is a pioneer in applying AI to solve complex cardiometabolic health challenges,” said Michael Sanky, VP, Industry GTM Leader at Databricks. “By building on the Databricks Data Intelligence Platform, Welldoc can unify all their data, delivering hyper-personalized interventions at scale with FDA-cleared solutions.”
Welldoc’s platform, backed by 11 FDA 510(k) clearances and over 90 clinical publications, has been recognized as the “Best Overall Digital Health Company” by MedTech Breakthrough for three consecutive years. Its recent collaboration with Lilly to power the Lilly Health™ app further demonstrates its leadership in cardiometabolic care. The partnership with Databricks, supported by HIPAA-compliant data governance, positions Welldoc to scale its impact, enhancing health outcomes and reducing costs for health plans, systems, and employers.
This expanded partnership empowers Welldoc to deliver transformative, AI-driven solutions, redefining personalized care for cardiometabolic conditions in 2025 and beyond.
Welldoc®, a digital health leader revolutionizing cardiometabolic care, integrates personalized, real-time and actionable insights into the daily lives of individuals living with cardiometabolic conditions, facilitating improved health and outcomes. Welldoc’s comprehensive digital health platform offers AI-powered digital coaching for pre-diabetes, diabetes, hypertension, heart failure and weight and obesity management, with integrated mental well-being and sleep support. As a FDA-cleared digital health solution, Welldoc guides individuals through the complex journey of living with diabetes, enabling self-management while enhancing connections with their healthcare team. The company partners with health plans, health systems and employers to extend care, improve health and reduce costs.
Welldoc has achieved 11 510(k) clearances for diabetes functionality within its digital health platform and holds an IP portfolio of 50+ patents for its advanced AI and first-in-class technology. With more than 90 clinical publications, Welldoc has built an extensive library of clinical research, including many publications focused on the value of combining CGM with AI-powered digital health solutions. Recognized as an industry thought leader, Welldoc has been featured in prestigious conferences and publications, including South by Southwest, the Wall Street Journal and the Economist. The company has been named the “Best Overall Digital Health Company” by MedTech Breakthrough for the past three years, and was a winner of the 2024 Healthcare AI Impact Awards, Innovation Awards by Business Intelligence Group, and Top 100 Healthcare Technology Companies by the Healthcare Technology Report.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.